Skip to main content
SpringerLink
Log in

Management of Acinetobacter Infections in the Immunosuppressed Host

  • Reference work entry
  • First Online:
Emerging Transplant Infections

  • 1093 Accesses

Abstract

Acinetobacter infections have emerged as an important pathogen in transplant recipients. It is a major cause of multidrug-resistant nosocomial infections, particularly pneumonia and bloodstream infections, and is associated with high morbidity and mortality. Given the organism’s propensity to develop resistance to multiple classes of antibiotics, treatment options can be limited but frequently include carbapenems, polymyxins, sulbactams, tetracyclines, and glycylcyclines. Infection prevention measures are critical for preventing transmission among patients and avoiding hospital outbreaks.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409–47.

    Article  CAS  PubMed  Google Scholar 

  2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939–51.

    Article  CAS  PubMed  Google Scholar 

  3. Phillips M. Acinetobacter species. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, updated edition. Philadelphia: Saunders; 2015. p. 2552–8.

    Chapter  Google Scholar 

  4. Cerezales M, Xanthopoulou K, Ertel J, Nemec A, Bustamante Z, Seifert H, et al. Identification of acinetobacter seifertii isolated from bolivian hospitals. J Med Microbiol. 2018;67(6):834–7.

    Article  CAS  PubMed  Google Scholar 

  5. Al Atrouni A, Joly-Guillou ML, Hamze M, Kempf M. Reservoirs of non-baumannii Acinetobacter species. Front Microbiol. 2016;7:49.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Weinstein RA, Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848–54. Available from: https://academic.oup.com/cid/article-lookup/doi/10.1086/432803

    Article  Google Scholar 

  7. Kollef MH, Shorr A, Tabak YP et al. Epidemiology and Outcomes of Health-care-Associated Pneumonia*. Chest. 2005;128(6):3854–62.

    Google Scholar 

  8. Dananché C, Vanhems P, Machut A, Aupée M, Bervas C, L’Hériteau F, et al. Trends of incidence and risk factors of ventilator-associated pneumonia in elderly patients admitted to French ICUs between 2007 and 2014. Crit Care Med. 2018;46(6):869–77.

    Article  PubMed  Google Scholar 

  9. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184(12):1409–17.

    Article  PubMed  Google Scholar 

  10. Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:1–8.

    Article  CAS  Google Scholar 

  11. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–301.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Garnacho-Montero J, Timsit JF. Managing Acinetobacter baumannii infections. Curr Opin Infect Dis. 2019;32(1):69–76.

    Article  PubMed  Google Scholar 

  13. Visca P, Seifert H, Towner KJ. Acinetobacter infection - an emerging threat to human health. IUBMB Life. 2011;63:1048–54.

    Article  CAS  PubMed  Google Scholar 

  14. Thom KA, Johnson JK, Lee MS, Harris AD. Environmental contamination because of multidrug-resistant Acinetobacter baumannii surrounding colonized or infected patients. Am J Infect Control. 2011;39(9):711–5.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E, Calleja I, et al. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care. 2012;16(3):R93.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Weber DJ, Anderson D, Rutala WA. The role of the surface environment in healthcare-associated infections. Curr Opin Infect Dis. 2013;26:338–44.

    Article  PubMed  Google Scholar 

  17. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumanni. Antimicrob Agents Chemother. 2007;51(10):3471–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–62.

    Article  PubMed  Google Scholar 

  19. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.

    Article  CAS  PubMed  Google Scholar 

  20. CDC. Antibiotic resistance threats in the United States, 2013 | antibiotic/antimicrobial resistance | CDC. CDC. 2013.

    Google Scholar 

  21. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–27.. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29276051

    Article  PubMed  Google Scholar 

  22. Kitazono H, Rog D, Grim SA, Clark NM, Reid GE. Acinetobacter baumannii infection in solid organ transplant recipients. Clin Transpl. 2015;29(3):227–32.

    Article  Google Scholar 

  23. Serifoglu I, Dedekarginoglu BE, Bozbas SS, Akcay S, Haberal M. Clinical characteristics of Acinetobacter baumannii infection in solid-organ transplant recipients. Exp Clin Transplant. 2018;16:171–5.

    PubMed  Google Scholar 

  24. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RCA, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One. 2012;7(12):e52349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kim YJ, Yoon JH, Kim SI, Hong KW, Kim JI, Choi JY, et al. High mortality associated with acinetobacter species infection in liver transplant patients. Transplant Proc. 2011;43(6):2397–9.

    Article  CAS  PubMed  Google Scholar 

  26. Trottier V, Namias N, Pust DG, Nuwayhid Z, Manning R, Marttos AC Jr, et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect. 2007;8(4):437–44.

    Article  Google Scholar 

  27. Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis. 2011;70(2):246–52.

    Article  CAS  PubMed  Google Scholar 

  28. de Gouvêa EF, Martins IS, Halpern M, Ferreira ALP, Basto ST, Gonçalves RT, et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection. BMC Infect Dis. 2012;12:351.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ellis D, Cohen B, Liu J, Larson E. Risk factors for hospital-acquired antimicrobial-resistant infection caused by Acinetobacter baumannii. Antimicrob Resist Infect Control. 2015;4(1):40.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kim YJ, Kim SI, Lee YD, Choi HJ, Choi JY, Yoon SK, et al. Carbapenem-resistant Acinetobacter baumannii bacteremia in liver transplant recipients. Transplant Proc. 2018;50(4):1132–5.

    Article  CAS  PubMed  Google Scholar 

  31. George RS, Birks EJ, Haj-Yahia S, Bowles CT, Hall A, Khaghani A, et al. Acinetobacter Mediastinitis in a heart transplant patient. Ann Thorac Surg. 2006;82(2):715–6.

    Article  PubMed  Google Scholar 

  32. Choe YM, Park KM, Jeon YS, Cho SG, Hong KC, Shin WY, et al. Abscess of native kidney caused by Carbapenem-resistant Acinetobacter baumannii (CRAB) in renal transplantation: a case report. Transplant Proc. 2016;48(3):949–50.

    Article  PubMed  Google Scholar 

  33. Patel G, Perez F, Hujer AM, Rudin SD, Augustine JJ, Jacobs GH, et al. Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient. Transpl Infect Dis. 2015;17(2):289–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Clemente WT, Sanches MD, Coutinho RL, De Oliveira Júnior AR, Lauria MW, Lima CX, et al. Multidrug-resistant acinetobacter baumannii causing necrotizing fasciitis in a pancreas-kidney transplant recipient: a case report. Transplantation. 2012;94(6):e37–8.

    Article  PubMed  Google Scholar 

  35. Zhong L, Men TY, Li H, Peng ZH, Gu Y, Ding X, et al. Multidrug-resistant gram-negative bacterial infections after liver transplantation - Spectrum and risk factors. J Infect. 2012;64(3):299–310.

    Article  PubMed  Google Scholar 

  36. Kroth LV, Barreiro FF, Saitovitch D, Traesel MA, d’Avila DOL, Poli-de-Figueiredo CE. Does thymoglobulin induction increase susceptibility to Carbapenem-resistant Acinetobacter baumannii Sepsis-related death in expanded criteria donors? Transplant Proc. 2016;48(7):2294–7.

    Article  CAS  PubMed  Google Scholar 

  37. Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL. Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients. Lung. 2010;188(5):381–5.

    Article  CAS  PubMed  Google Scholar 

  38. Wojarski J, Ochman M, Medrala W, Kulaczkowska Z, Karolak W, Maruszewski M, et al. Bacterial infections during hospital stay and their impact on mortality after lung transplantation: a single-center study. Transplant Proc. 2018;50(7):2064–9.

    Article  CAS  PubMed  Google Scholar 

  39. Almutairy, Eid, Alshekaily, Naseer, Khan, Basha, Saleh, Waleed, Nizami I. Prevalence and outcome of donor transmitted Acinetobacter baumannii in lung transplant patients in Saudi Arabia. European Respiratory Journal, Annual Congress 2012; 40:P2448.

    Google Scholar 

  40. Cohen J, Michowiz R, Ashkenazi T, Pitlik S, Singer P. Successful organ transplantation from donors with Acinetobacter Baumannii septic shock. Transplantation. 2006;81(6):853–5.

    Article  PubMed  Google Scholar 

  41. Mularoni A, Bertani A, Vizzini G, Gona F, Campanella M, Spada M, et al. Outcome of transplantation using organs from donors infected or colonized with Carbapenem-resistant gram-negative Bacteria. Am J Transplant. 2015;15(10):2674–82.

    Article  CAS  PubMed  Google Scholar 

  42. Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321–31.

    Article  PubMed  Google Scholar 

  43. Ortega M, Rovira M, Almela M, Marco F, de la Bellacasa JP, Martínez JA, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol. 2005;84(1):40–6.

    Article  PubMed  Google Scholar 

  44. Kim SB, Min YH, Cheong JW, Kim JS, Kim SJ, Ku NS, et al. Incidence and risk factors for carbapenem-and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis. 2014;46(2):81–8.

    Article  PubMed  CAS  Google Scholar 

  45. Wisplinghoff H, Paulus T, Lugenheim M, Stefanik D, Higgins PG, Edmond MB, et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J Infect. 2012;64(3):282–90.

    Article  PubMed  Google Scholar 

  46. Jeong S, Hong JS, Kim JO, Kim KH, Lee W, Bae IK, et al. Identification of acinetobacter species using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Ann Lab Med. 2016;36(4):325–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Sousa C, Botelho J, Grosso F, Silva L, Lopes J, Peixe L. Unsuitability of MALDI-TOF MS to discriminate Acinetobacter baumannii clones under routine experimental conditions. Front Microbiol. 2015;6(MAY):481.

    PubMed  PubMed Central  Google Scholar 

  48. Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii. Virulence. 2012;3(3):243–50.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Pasanen T, Koskela S, Mero S, Tarkka E, Tissari P, Vaara M, et al. Rapid molecular characterization of Acinetobacter baumannii clones with rep-PCR and evaluation of carbapenemase genes by new multiplex PCR in Hospital District of Helsinki and Uusimaa. PLoS One. 2014;9(1):e85854.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Chuang YC, Chang SC, Wang WK. Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia. Crit Care Med. 2012;40(8):2273–80.

    Article  CAS  PubMed  Google Scholar 

  51. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance — treatment options. Semin Respir Crit Care Med. 2015;36(1):85–98.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Pouch SM, Patel G. Multidrug-resistant gram-negative bacterial infections in solid organ transplant recipients – guidelines from the American Society of Transplantation infectious diseases Community of Practice. Clin Transpl. 2019;33(9):e13594.

    Article  Google Scholar 

  53. Maragakis LL, Perl TM. Antimicrobial resistance: acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–63.

    Google Scholar 

  54. Skariyachan S, Taskeen N, Ganta M, Venkata Krishna B. Recent perspectives on the virulent factors and treatment options for multidrug-resistant Acinetobacter baumannii. Crit Rev Microbiol. 2019;45(3):315–333.

    Google Scholar 

  55. Bulens SN, Yi SH, Walters MS, Jacob JT, Bower C, Reno J, et al. Carbapenem-nonsusceptible acinetobacter baumannii, 8 US metropolitan areas, 2012-2015. Emerg Infect Dis. 2018;24(4):727–34.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Fishbain J, Peleg AY. Reviews of anti-infective agents: treatment of acinetobacter infections. Clin Infect Dis. 2010;51(1):79–84.

    Google Scholar 

  57. Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother. 2010;11(5):779–88.

    Article  CAS  PubMed  Google Scholar 

  58. Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49(2):233–8.

    Article  CAS  PubMed  Google Scholar 

  59. Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, et al. Colistin-resistant acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295–303.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, et al. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL surveillance 2010. Diagn Microbiol Infect Dis. 2012;73(3):267–70.

    Google Scholar 

  61. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36(9):1111–8.

    Article  CAS  PubMed  Google Scholar 

  62. Kwa ALH, Loh C, Low JGH, Kurup A, Tam VH. Nebulized Colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2005;41(5):754–7.

    Article  PubMed  Google Scholar 

  63. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant pseudomonas aeruginosa and acinetobacter baumannii. Anesthesiology. 2012;117(6):1335-47.

    Google Scholar 

  64. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by gram-negative bacteria. J Antimicrob Chemother. 2010;65(12):2645–9.

    Article  CAS  PubMed  Google Scholar 

  65. Demirdal T, Sari US, Nemli SA. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann Clin Microbiol Antimicrob. 2016;15:11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013;41:499–508.

    Article  CAS  PubMed  Google Scholar 

  67. Cascio A, Conti A, Sinardi L, Iaria C, Angileri FF, Stassi G, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis. 2010;14(7):e572–9.

    Article  PubMed  Google Scholar 

  68. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 2008;56(6):432–6.

    Article  PubMed  Google Scholar 

  69. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-Sulbactam and imipenem-Cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34(11):1425–30.

    Article  CAS  PubMed  Google Scholar 

  70. Niu T, Luo Q, Li Y, Zhou Y, Yu W, Xiao Y. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii. Antimicrob Resist Infect Control. 2019;8:52.

    Google Scholar 

  71. Jeong IB, Na MJ, Son JW, Jo DY, Kwon SJ. High-dose Sulbactam treatment for ventilator-associated pneumonia caused by Carbapenem-resistant Acinetobacter Baumannii. Korean J Crit Care Med. 2016;31(4):308–16.

    Article  Google Scholar 

  72. Chen H, Liu Q, Chen Z, Li C. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis. J Infect Chemother. 2017;23(5):278–85.

    Article  CAS  PubMed  Google Scholar 

  73. Lashinsky JN, Henig O, Pogue JM, Kaye KS. Minocycline for the treatment of multidrug and extensively drug-Resistant A. baumannii: a review. Infect Dis Ther. 2017;6:199–211.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Goff DA, Kaye KS. Minocycline: an old drug for a new bug: multidrug-resistant acinetobacter baumannii. Clin Infect Dis. 2014;59(Suppl 6):S365–6.

    Article  CAS  PubMed  Google Scholar 

  75. Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program’s evaluation of minocycline for multidrug-resistant acinetobacter baumannii infections. Clin Infect Dis. 2014;59(Suppl 6):S381–7.

    Article  CAS  PubMed  Google Scholar 

  76. Ni W, Han Y, Zhao J, Wei C, Cui J, Wang R, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47(2):107–16.

    Article  CAS  PubMed  Google Scholar 

  77. Tucker H, Wible M, Gandhi A, Quintana A. Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 phase III and phase IV clinical trials. Infect Drug Resist. 2017;10:401–417.

    Google Scholar 

  78. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36(9):1111–8.

    Google Scholar 

  79. Heaney M, Mahoney MV, Gallagher JC. Eravacycline: the tetracyclines strike back. Ann Pharmacother. 2019;53(11):1124–1135.

    Google Scholar 

  80. Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63(1):e01110–8.

    Article  CAS  PubMed  Google Scholar 

  81. Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: to combine or not to combine? Antibiotics. 2019;8(2):E38.

    Article  PubMed  CAS  Google Scholar 

  82. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–22.

    Article  CAS  PubMed  Google Scholar 

  83. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.

    Article  CAS  PubMed  Google Scholar 

  84. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–601.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400.

    Article  CAS  PubMed  Google Scholar 

  86. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23(10):704–12.

    Article  CAS  PubMed  Google Scholar 

  87. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42(5):692–9.

    Article  PubMed  Google Scholar 

  88. Jawad A, Snelling AM, Heritage J, Hawkey PM. Exceptional desiccation tolerance of Acinetobacter radioresistens. J Hosp Infect. 1998;39(3):235–40.

    Google Scholar 

  89. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977–2000. Infect Control Hosp Epidemiol. 2003;24(4):284–95.

    Article  PubMed  Google Scholar 

  90. Rodríguez-Baño J, García L, Ramírez E, Martínez-Martínez L, Muniain MA, Fernández-Cuenca F, et al. Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive “bundle” approach. Am J Infect Control. 2009;37(9):715–22.

    Google Scholar 

  91. Gray AP, Allard R, Paré R, Tannenbaum T, Lefebvre B, Lévesque S, et al. Management of a hospital outbreak of extensively drug-resistant Acinetobacter baumannii using a multimodal intervention including daily chlorhexidine baths. J Hosp Infect. 2016;93(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  92. Fitzpatrick MA, Ozer EA, Hauser AR. Utility of whole-genome sequencing in characterizing acinetobacter epidemiology and analyzing hospital outbreaks. J Clin Microbiol. 2016;54(3):593–612.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Chen CH, Lin LC, Chang YJ, Liu CE, Soon MS. Long-term effectiveness of infection and antibiotic control programs on the transmission of carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex in Central Taiwan. Med Mal Infect. 2015;45(7):264–72.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Cheon S, Kim MJ, Yun SJ, Moon JY, Kim YS. Controlling endemic multidrug-resistant acinetobacter baumannii in intensive care units using antimicrobial stewardship and infection control. Korean J Intern Med. 2016;31:367–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatmentof ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Emily Baneman & Meenakshi M. Rana

Authors
  1. Emily Baneman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meenakshi M. Rana
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meenakshi M. Rana .

Editor information

Editors and Affiliations

  1. Immunocompromised Host Service Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

  2. Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Camille Nelson Kotton

  3. Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

    Cameron R. Wolfe

Section Editor information

  1. Duke University, Durham, NC, USA

    Cameron R. Wolfe

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Baneman, E., Rana, M.M. (2021). Management of Acinetobacter Infections in the Immunosuppressed Host. In: Morris, M.I., Kotton, C.N., Wolfe, C.R. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-25869-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25869-6_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25868-9

  • Online ISBN: 978-3-030-25869-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation